Testing a simple system to recognize acromegaly
Part of Bones, joints & muscles, Brain & nervous system, Hormones & metabolism clinical trials.
This study tests a simple recognition tool to help tell whether someone has acromegaly or not. It may be useful for faster, easier identification of the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 80 years old
- You are either an acromegaly patient or a healthy adult
- You are not pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called MAR002 to treat acromegaly, a hormone disorder caused by a pituitary tumor that makes too much growth hormone. The drug is designed to help lower hormone levels and improve symptoms.
This study looks at what makes bones strong or weak in people with acromegaly (a condition that causes too much growth hormone). It aims to find better ways to check bone health and prevent fractures.
This early-phase trial tests a new investigational drug called MAR002 in healthy men. The goal is to see how safe the drug is and how the body handles it before moving to larger studies.
This study follows people with acromegaly to better understand how treatments are used in real life and how well they work over time. It may help improve future treatment choices by comparing outcomes across different care patterns.
This study looks at how treatments for acromegaly affect how you function and move, especially in your hands, feet, and overall body structure. You may be asked to do assessments to understand changes over time and whether certain groups respond differently.
This trial tests a new medication, Debio 4126, for people with acromegaly who are already being treated with octreotide or lanreotide. The goal is to see if it can help control hormone levels and is safe to use.
Hear when a new Acromegaly trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.